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include = > 1 cohorts, retrospective or prospective data collection, disease or treat-
ment-based inclusion criteria, various outcomes (safety, prescription pattern or 
off-label use, comparative effectiveness, quality of life or other patient-reported 
outcomes[PRO], health economics, or other objectives), site/investigator selection 
(in-house, commercial, professional organization, or government databases), and 
country-specific requirements. Methods: Studies that used integrated and non-
integrated DM systems were evaluated to identify criteria for use and associated 
protocol template language (PTL), including required, preferred, or optional text 
based on various study designs and objectives. Results: Multiple DM systems were 
evaluated and algorithms created with use criteria. For integrated DM systems that 
combined data capture and trial management, simplified PTL was identified. DM 
PTL was adjusted to include paper or electronic data capture (EDC) methods, paper/
electronic-based PROs, paper/electronic case report forms (CRFs), data (eg. subject/
physician entered, site or aggregate, medical or laboratory records) and appropriate 
subject data protection. For non-integrated systems that required separate DM and 
trial management, additional PTL was identified for these complex DM systems. The 
templates denoted minimum required language and suggested extended language 
for more elaborate designs. To support the numerous NIS study design types, we 
included decision trees to account for various study goals, associated outcomes, 
and data collection requirement. Our data collection decision tree summarized the 
variety of potential study designs with frequently used study goals/outcomes and 
associated data collection techniques. ConClusions: Integrated DM systems pro-
vided the most flexibility and simplicity of protocol template language. All template 
language was created as adjustable to meet the typical study designs encountered 
in PASS studies. This additional information was to support the protocol devel-
opment team in creating the final protocol in a timely manner and in reviewing 
client-provided templates.
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objeCtives: Conducting real world evidence (RWE) research on patients with rare 
diseases is particularly challenging when using only one type of data (e.g. insur-
ance claims). Myelofibrosis (MF) is a rare, hematological cancer with global annual 
incidence rate of < 1 - 2.4 cases per 100,000 patients. MF is characterized by the 
reduced ability of bone marrow to synthesize blood cells which can result in anemia, 
thrombocytopenia, and higher risk of infection. Absent adequate, recent data on MF 
patients, a practice-based network (PBN) data platform was developed to facilitate 
RWE research on MF patients. Methods: MF patients observed in IMS Health data-
bases between November 2010 to October 2012 were identified. Academic centers of 
excellence and large community oncology practices treating MF patients were then 
identified to link additional patients into the platform using a HIPAA-compliant 
patient de-identification algorithm. Patient demographics and attributes of dis-
pensed prescriptions, private practitioner visits, and electronic medical record data 
including laboratory information were collected across patients from January 2000 
to March 2013. Descriptive analyses of demographic and clinical characteristics were 
conducted to assess the generalizability of the sample versus literature. Results: 
A total of 6362 U.S. MF patients were identified in the platform. Mean (SD) age was 
67 (12.6) and 45% of patients were female. Mean (SD) Charlson Comorbidity Index 
was 4.36 (2.4). Among the subset of 529 patients with laboratory results, 63% were 
identified as anemic and 34% had platelet counts 50,000 - 100,000 / microL. All U.S. 
geographic regions were represented. ConClusions: Demographic and clinical 
results suggest that this large sample of MF patients is comparable to prior esti-
mates of the broader MF population. This case study of U.S. MF patients suggests it 
is important to look beyond any one data source and to build PBN platforms with 
key clinical domains spanning multiple geographic regions when conducting RWE 
research on patients with rare diseases.
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objeCtives: Observational studies are often planned on an ad hoc basis, with 
the risk that methods are inconsistent and that aims overlap rather than comple-
ment each other. Our objective was to develop a systematic approach for identify-
ing observational data sources for an integrated global programme of real-world 
evidence gathering, to support an important new indication for an antiplatelet 
drug. Methods: Systematic literature and Web searches, supplemented with email 
and telephone contact with data owners, were used to identify and characterize 
registries and health care databases suitable for use in observational studies of 
myocardial infarction and acute coronary syndromes. The ability to identify patients 
across data sources was also assessed. Data were captured and evaluation criteria 
applied, including compatibility with aspects of an ongoing randomized clinical 
trial (patient population, treatments, outcomes, and length of follow-up [≥ 3 years]). 
Selection criteria included accessibility; availability of inpatient, outpatient, cardiac 
event, and drug data; and generalizability. Results: Over 2700 publications were 
screened; we identified 216 registries and 380 databases (primarily of administra-
tive claims and electronic medical records). Of these, 12 registries, and 21 databases 
met the evaluation criteria and were assessed in depth. After application of the 
selection criteria, 5 registries and 12 databases were recommended. Recommended 
data sources ranged in size, each capturing data on between 4000 and 11 million 
the user’s behavior upon navigating the site. Results: Since the site began to get 
monitored on July 1, 2012 and up until June 25, 2013, 19.738 hits were registered, with 
a monthly average of 1.661 hits. More than 65 countries accessed the site, the major-
ity coming from the USA, UK and Portugal. Brazil leads with 93%. The rate of return 
of people who frequently accessed the site was 24,7%. Upon navigating the site, 
more than 45.000 visualizations of the web page were registered. ConClusions: 
This monitoring began in 2012 and therefore no previous years exist to serve as a 
basis for comparison. The results show that a considerable number of users have 
access to the site and consequently know about REBRATS. From the perspective of 
the website, the number of hits is still low, however, considering that the HTA field 
is a recent one in Brazil, its growth has been gradual. On an international level, 
new dissemination strategies are necessary in order to create greater visibility and 
promotion of the network.
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objeCtives: Identifying treatment pathways based on administrative data or elec-
tronic medical records is generally a complex task, as many incidental events may 
hide the key trends. The purpose of this study was to propose a transparent method-
ology for defining treatment pathways using a large longitudinal real life database. 
The application of two alternative algorithms with different variants in Parkinson’s 
disease (PD) was described. Methods: In the first method, a new treatment line 
was assumed to start when a pre-specified number of consecutive prescriptions of 
drugs from the same PD drug class or combination of classes (rasagiline, selegiline, 
dopa agonists, COMT inhibitors, levodopa and derivatives) occurred. In the second 
method, start and end dates of continuous treatment periods (i.e. without gaps 
higher than six months between prescriptions) were determined for each drug class 
independently of each other. Combinations were assumed to be used when differ-
ent treatment periods overlapped. Algorithms were tested using medical records 
of patients with Parkinson’s disease (PD) extracted from the UK Clinical Practice 
Research Datalink (CPRD). The outputs of the different algorithms were described 
in details for ten patients, randomly selected. The sensitivity of the algorithms to 
changes in assumptions was tested. Results: The first algorithm did not systemat-
ically capture the addition of a new drug to the current treatment as combined drugs 
were not necessarily prescribed or renewed during the same consultations. However, 
the second method well captured the treatment lines observed but sometimes cre-
ated undue treatment lines from isolated prescriptions. This issue was overcome 
by deleting short lines lasting less than three months. ConClusions: The second 
algorithm developed in this study provided an accurate description of the treatment 
strategies developed by prescribers in Parkinson’s disease in the UK using a limited 
number of assumptions and may be useful for other chronic diseases.
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objeCtives: To identify and assess real world data sources for observational 
research on lymphoma and multiple myeloma (myeloma) in Europe. Methods: 
Structured (EMBASE and MedLine) and grey literature searches were conducted 
to identify relevant European data sources. Identified data sources were screened 
based on the following criteria: inclusion of patient-level data and patients with 
NHL, HL, or MM diagnoses, possession of data dictionaries, and ongoing data accrual. 
Where regional registries were proven to feed data into national registries, only 
the national data source was retained for evaluation. Data sources passing initial 
screening were subjected to further evaluation based on publicly reported infor-
mation, questionnaires and / or interviews with data source owners, and informed 
by lymphoma and myeloma treatment pathway analysis. Results: One hundred 
eighty-six data sources from 21 countries were identified; of which cancer regis-
tries (R) accounted for 65%. The remaining 35% non-registry (NR) sources included 
biobanks, clinical audits, data linkage initiatives, drug databases and electronic 
medical records. Screening removed 101 sources. Of the 85 sources retained after 
screening, roughly half (52%) were NR sources and a majority (74%) were from six 
countries: France, Germany, Spain, Sweden, The Netherlands, and The UK. NR data 
sources generally collected more data attributes than R data sources. These data 
attributes included symptoms (collected by 52% NR, and 21% R data sources), treat-
ment regimens (81% NR, 40% R), and resource use (49% NR, 8% R). ConClusions: 
Compared with disease registries, non-registry data sources in Europe typically have 
more diverse data attributes and are therefore potentially better for lymphoma and 
myeloma research. This result may guide the selection of data sources for observa-
tional research. As scrutiny of real-world outcomes for reimbursement of oncology 
drugs increases, much work remains to be done to increase the visibility and utility 
of data sources for health care payers and providers.
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objeCtives: To address non-interventional study (NIS) protocol DM and data 
collection requirements in PASS observational study designs. These studies may 
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objeCtives: Access to large-scale public health claims databases is limited due 
to privacy concerns and lack of a unique identifier in Japan. Since such databases 
were not originally designed for outcomes research, we assessed the usefulness 
of one of the commercial databases in identifying treatment patterns in routine 
clinical practice. Methods: Treatment patterns for patients with exudative age-
related macular degeneration (AMD) using anti-vascular endothelial growth factor 
(anti-VEGF) was selected as an example to enhance our understanding of real-
world clinical practice. A retrospective open-cohort study of patients diagnosed 
with AMD and treated from January 2010 to December 2012 at community hospitals 
employing Diagnostic Procedure Combination payment system was conducted by 
using hospital claims database provided by Medical Data Vision, Co., Ltd. Strengths 
and weaknesses of using the database were also identified. Results: During the 
study period, 248 patients were diagnosed with AMD and received ranibizumab, 
19 patients received pegaptanib, and two patients received aflibercept. Among the 
patients who received ranibizumab, the average number of ranibizumab injec-
tions per year was 3.21±2.38. The strength of the database was granularity of 
data including daily medication and medical procedural histories that allow us to 
obtain key parameters of analyzing treatment patterns. A major weakness was no 
unique identifier for patients; thus, a patient would be recorded as two different 
entries in the database if s/he visited two different hospitals. ConClusions: 
The results show that the commercial hospital claims database was useful to 
understand treatment patterns of exudative AMD at non-university hospital set-
tings. Since treatment guidelines are usually written based on published clinical 
trial evidence, this type of database research provides an understanding of real 
life clinical practice and its associated patient outcomes, contributing to better 
adherence and future updates of treatment guidelines.
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objeCtives: To compare official prices and refunding limits of the selected drugs 
with the prices and limits used in the manufacturers’ Budget Impact Analyses 
(BIAs) submitted in the reimbursement applications and in the manufactur-
ers’ documentations from request for removing, altering the level or method of 
financing of medicines to AHTAPol and to verify the accuracy of their assump-
tions. Methods: Prices and limits proposed in BIAs in years 2007-2011 and 
official prices and limits for the same medicine were compared. Only BIAs for 
medicines which had been reimbursed for at least one year were included in 
the analysis. The official prices and limits were obtained from reimbursed drugs 
list published in Ministry of Health’s Orders. Results: In the studied period, 
72 drugs were included in the analysis. Among them, 51,39% (37/72) were from 
reimbursement applications and 48,61% (35/72) were from requests for remov-
ing, altering the level or method of financing of medicines, respectively. As 
a result, 13% (9/72) of the prices proposed in the BIAs were underestimated. 
Median and mean difference (MD) between official prices and prices used in 
BIAs for the same medicine were 95% and 91% respectively. The overestimation 
was found in 39% BIAs (28/72); median = 117%, MD = 124%. Rest of the prices 
were equal 49% (35/72). Limits were underestimated in 8% (6/72) of the BIAs. 
Median and mean difference between official prices and prices used in BIAs 
were 97% and 98% respectively. Overestimation of the limits was found in 57% 
(41/72) of the BIAs; median = 133%, MD = 117%. Rest of the limits were equal 35% 
(25/72). ConClusions: Among the contradictory prices and limits official ones 
were higher than the prices assumed in BIAs for the same medicines. There is a 
strong need for further research.
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objeCtives: Many public health decisions are made based on information con-
tained in medical publications. Therefore developing a publication strategy is a 
benefit for the pharmaceutical industry as it ensures an efficient dissemination of 
drug efficacy and safety evidence and an ethic development of the publications. In 
the context of outcome research, a publication strategy should take into considera-
tion specific aspects related to the field (e.g., dealing with local, regional and global 
levels) and is important to ensure that unbiased information is provided to medical 
decision makers on time for the good of public health. A literature review was con-
ducted to investigate if published guidelines on the development of a publication 
strategy in the context of outcome research exist. Methods: A literature search 
of English articles was conducted on MEDLINE and Scopus. Search terms included 
“publication strategy” OR “publication planning” OR “publication coordination” 
AND “health economics” OR “health outcome” OR “outcome research” OR “medical 
economics”. Independent extraction of articles was performed using predefined 
data fields. Results: The search provided four citations; all were discarded after 
reviewing the abstracts. However, a simple search for the keywords “publication 
strategy” OR “publication planning” returned 85 hits in fields as various as psychol-
ogy, political science, environmental science and medicine. None of the citations 
was specific to outcome research. ConClusions: The results of the literature 
search showed that the development of a publication strategy is an important 
concept through many different domains. However, no published guideline on 
the development of a publication strategy in the context of outcome research 
was found. A publication strategy specific to outcome research publications will 
be presented including recommendations regarding the key aspects that should 
be covered in an efficient outcome research publication strategy such as a criti-
cal assessment of published literature, identification of gaps, and development 
of a strategic plan.
patients, and were geographically diverse, representing populations in Europe, the 
USA, and Australia. Each recommended data source had unique strengths and limi-
tations for use in real-world evidence studies, and together they had the potential 
to provide consistent and complementary information. The study output provided 
a valuable tool for global and local investigators. ConClusions: Observational 
data sources are diverse. A systematic understanding of real-world evidence can 
guide the development of a coherent strategy for designing observational studies 
to support clinical research.
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objeCtives: To assess the feasibility of use of medical-transcription data for 
real-world clinical evidence generation in the US. Methods: Majority of clini-
cal practices in the US are experimenting digitization of patient medical records 
for two reasons: patient-management/care-delivery and billing/administrative/
legal documentation purposes. Increasingly, physicians are using medical-tran-
scription services, where physicians dictate details of patient visits and send the 
voice-recording-device to medical-transcription organization which processes 
voice-data and delivers electronic-files back to clinics; physicians review/revise/
append the electronic-documentation and adds data to their patient-database-
repository for future use. This pilot study assessed the utility of de-identified med-
ical-transcription data in evaluating patient-physician dynamics and real-world 
treatment patterns/outcomes and documented adverse-events(AEs) using random 
set of adult SLE patients who initiated belimumab (a recently-launched biologic) 
within the past 2years as part of usual care. SLE was chosen specifically because of 
its complex clinical management issues. Results: Nineteen belimumab patient 
transcription-records (de-identified) were reviewed (mean age:39.4yrs; female:95%). 
Top-4 clinical-manifestations at belimumab-start were: musculoskeletal(68%)/
mucocutaneous(53%)/constitutional(42%)/renal(21%). Physicians discussed beli-
mumab-attributes (specifically, infection-risks/AEs/etc), asked patients to do their 
own research on belimumab, and cited insurance/reimbursement-issues prior to 
belimumab-start in 58%, 26% & 26% of cases respectively; 11% of patients asked for 
belimumab. Top-3 documented-reasons for belimumab-start were: steroid-spar-
ing(32%), control autoimmune diathesis(11%), control SLE-flares(16%). In 47% of 
patients, belimumab (at initiation) replaced another medication (majority:steroids/
immunosuppressants); concomitant SLE-medications were: antimalarials(84%)/
oral-steroids(68%)/Immunosuppressants(47%). Average belimumab-duration was 
8.1months (overall data availability/patient:23.8months). During the observation 
period, 42% had > = 1AE (e.g., diarrhea/rash/bronchiolitis/alopecia/upper-respira-
tory-track-infection), 42% discontinued belimumab (but 26% re-started) and 47% 
had some physician-documented improvement in outcomes (e.g., joint-pain/
rash/energy level/fatigue). One patient had documented steroid-stoppage post-
belimumab initiation. ConClusions: Medical-transcription data may provide 
documented real-world evidence of treatment dynamics and clinical status/out-
comes associated with patient care. In this random cohort of SLE patients using 
belimumab, belimumab appears to provide some demonstrable benefits in almost 
half of the patients.
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objeCtives: In 2002, PROQOLID was launched to provide an overview of existing 
PRO instruments and a facilitated access to the instruments and their develop-
ers through the structured presentation of synthesized, reliable, and constantly 
updated data. With the constant growth of electronic capture of patient-reported 
outcomes, detailing information about modes of data collection (i.e., paper vs. 
electronic) in PROQOLID might become a crucial step in updating the database. 
The objective of this study was: (1) To review how e-PROs are currently reported 
in PROQOLID; and (2) To propose (if needed) ways of clarifying and updating e-PRO 
information. Methods: PROQOLID was searched to retrieve current information 
about e-PROs using an advanced search engine. Results: The e-PRO information 
was found under the category “mode of administration.” Three options could be 
chosen: computer-administered, electronic-administered, and IVR (Interactive Voice 
Response) version. Out of the 751 instruments in the database, 37 (5%) were reported 
with e-PRO information. Information about existing translations of electronic ver-
sions was clearly specified for three questionnaires. To clarify and update e-PRO 
information in PROQOLID, several recommendations are proposed: (1) To create 
a new category, i.e., mode of data collection, in order to differentiate it from the 
“mode of administration” category; (2) To categorize each mode of data collection 
into five subcategories [i.e., Hand-Held Device, IVR, Internet web-data capture, Pen, 
and Tablet]; and (3) To provide a list of all translations available in each mode of 
data collection. ConClusions: This review has shown that PROQOLID already 
includes e-PRO information. Recommendations are given on how to modify the 
organization and content of the database to present the information on electronic 
capture of PROs.
PRM54
usefulness of a coMMeRcial hosPital claiMs dataBase to identify 
cuRRent anti-vasculaR endothelial gRoWth factoR tReatMent 
PatteRns in Patients With exudative age-Related MaculaR 
degeneRation in JaPan
Narimatsu A., Adachi K., Wang E.C.Y.
Bayer Yakuhin, Ltd., Tokyo, Japan
